Biotech Values

[DewDiligence]

AGN is trying to cash in on the aesthetic medical field, and they are not doing that well. Botox is being successfully challenged by Dysport…

That depends on how you define successfully. Botox’s market share in the US is 86% in cosmetic procedures and close to 100% in medical procedures. Worldwide, for all kinds of procedures, Botox’s market share is about 85%.

In the next year or so other competitors will enter the market.

It will be a little longer than that. JNJ’s BLA submission for PurTox is expected in 4Q10, so the US launch is unlikely to occur before late 2011 or early 2012.